In This Article:
JERUSALEM, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Dror Ortho-Design, Inc. ("Dror" or the "Company") (OTC PINK: DROR), a pioneer in AI-powered orthodontic solutions, today announced the successful completion of user experience trials for its ZSmile platform ahead of its commercial release.
This comprehensive user experience trial assessed the platform's usability among patients, orthodontists, and dental professionals under real operating conditions. The trial focused on user interaction with the system, complementing previous clinical trials that confirmed the treatment efficacy of Dror’s smile treatment system. Dror’s first-generation system, which received FDA clearance in 2020, has successfully treated over 250 patients across Israel and Europe.
"The successful completion of this usability trial validates our second-generation solution's intuitive design and seamless experience for both patients and practitioners. In addition to confirming the ease of use, the trial also demonstrated the comfort of using ZSmile and its non-interference with normal sleep," said Lee Haddad, Chief Executive Officer of Dror. "Our two-year investment in developing a sophisticated remote monitoring and patient management system has yielded a platform that tracks treatment compliance in real-time while providing vital and engaging feedback to all users. These trial results are assisting us in finalizing the commercial version to be ready for manufacturing and distribution, subject to regulatory approval in the first part of 2025."
The Company has already integrated all the feedback from the user experience trial and is completing its regulatory path to commence manufacturing and distribution of ZSmile in Israel in the first half of 2025.
Dr. Joel Becker DMD, MSc, accredited by Hadassah School of Dentistry and Orthodontic Consultant at Dror, commented, "With three decades of orthodontic practice and experience across treatment modalities from traditional braces to clear aligners, I recognize ZSmile as a significant technological advancement. The system effectively addresses Class I and Class II malocclusions with minimal discomfort and maximum discretion, filling a crucial market need."
In a separate survey conducted through a third-party service, the Company polled 1,000 randomly selected clear aligner patients. The findings revealed that 74% felt their aligners interfered with daily activities such as eating and speaking in public, 77% experienced discomfort while wearing them, and 93% expressed a preference for a nighttime solution that would gently shift their teeth while they sleep.